IgAN study: ADX-038 Dose Level
Official title Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
ClinicalTrials.gov ID: NCT06989359
What this study is testing
What is ADX-038?
An investigational drug being studied as a potential treatment for IgA nephropathy (IgAN). It is designed to use small interfering RNA to silence specific genes involved in complement-mediated kidney damage.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether ADX-038 is safe and works in adults with complement‑mediated kidney disease.
- Who it's for
- You may be able to join if you are an adult with IgA nephropathy, C3 glomerulopathy, or another complement‑mediated kidney disease.
- What's involved
- You would receive ADX-038, a medicine that targets the complement system, and have blood tests to check safety and how the drug behaves.
- Time commitment
- The study lasts several months with regular clinic visits for check‑ups and blood draws.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Mean eGFR greater than or equal to 30 mL/min/1.73m2
- Clinical evidence of active kidney disease
- Treated with supportive care including an ACE inhibitor or ARB if applicable
- Willing to receive required vaccinations
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
You likely can't join if
- Hereditary or acquired complement deficiency
- Kidney transplant or renal replacement therapy
- History of solid organ transplant
- Other kidney disease
- History of recurrent invasive infections
- Received complement inhibitor treatments
See the full eligibility criteria
- Mean eGFR greater than or equal to 30 mL/min/1.73m2
- Clinical evidence of active kidney disease
- Treated with supportive care including an ACE inhibitor or ARB if applicable
- Willing to receive required vaccinations
- Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy
- Hereditary or acquired complement deficiency
- Kidney transplant or renal replacement therapy
- History of solid organ transplant
- Other kidney disease
- History of recurrent invasive infections
- Received complement inhibitor treatments
- Active systemic viral, bacterial, or fungal infection
- Abnormal liver function
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
- Iowa City, Iowa, United States
- Shelby, Michigan, United States
- Great Neck, New York, United States
- Columbus, Ohio, United States
- Dakota Dunes, South Dakota, United States
- Houston, Texas, United States
- Liverpool, New South Wales, Australia
- Wollongong, New South Wales, Australia
- Sydney, Australia
- Woolloongabba, Australia
- Hong Kong, Hong Kong
- Shatin, Hong Kong
- Bergamo, Italy
- Bologna, Italy
- Pavia, Italy
- Wŏnju, Gangwon-do, South Korea
- Gyeonggi-do, Gurogu, South Korea
- Seoul, Gurogu, South Korea
- Cheonan, South Korea
+ 9 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States; Iowa City, Iowa, United States; Shelby, Michigan, United States; Great Neck, New York, United States; Columbus, Ohio, United States; Dakota Dunes, South Dakota, United States and 23 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.